For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Kai Pharmaceuticals, Inc.

USPTO Granted Patents = 19

% Expired Patents = 42.1

EPO Patents = 9

Forward Citations = 119

Loading Chart...

Loading Chart...

14 inventors (with patents filed for the assignee):

Derek Maclean (11 out of 19 patents)

Qun Yin (8 out of 30 patents)

Felix D Karim (8 out of 11 patents)

4. Amos Baruch (6 out of 6 patents)

5. Kanad Das (6 out of 6 patents)

6. Paul A Wender (3 out of 42 patents)

7. Mike Tso-Ping Li (3 out of 6 patents)

8. Jonathan B Rothbard (3 out of 22 patents)

9. Lalitha V S Sista (3 out of 8 patents)

10. Thorsten A Kirschberg (3 out of 8 patents)

11. Gregory Bell (2 out of 2 patents)

12. P Leo McGrane (2 out of 7 patents)

13. Sarah Walter (1 out of 5 patents)

14. Leo P McGrane (1 out of 1 patent)

15. James E Tomlinson (12 patents)

19 patents: Sort by Forward Citations

1. 10280198 - Therapeutic agents for reducing parathyroid hormone levels (2019-05-07),

2. 10077438 - Modifications of peptide compositions to increase stability and delivery efficiency (2018-09-18),

3. 9701712 - Therapeutic agents for reducing parathyroid hormone levels (2017-07-11),

4. 9567370 - Therapeutic agents for reducing parathyroid hormone levels (2017-02-14),

5. 9278995 - Therapeutic agents for reducing parathyroid hormone levels (2016-03-08),

6. 9255124 - Modifications of peptide compositions to increase stability and delivery efficiency (2016-02-09),

7. 8999932 - Therapeutic agents for reducing parathyroid hormone levels (2015-04-07),

8. 8987200 - Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders (2015-03-24),

9. 8969299 - Therapeutic agents for regulating serum phosphorus (2015-03-03),

10. 8729010 - Compositions and methods for enhancing drug delivery across and into ocular tissues (2014-05-20),

11. 8623833 - Compositions and methods for enhancing drug delivery across and into epithelial tissues (2014-01-07),

12. 8524673 - Pharmaceutical formulation (2013-09-03),

13. 8492346 - Methods of use of epsilon inhibitor compounds for the attenuation of pain (2013-07-23),

14. 8377880 - Therapeutic agents for reducing parathyroid hormone levels (2013-02-19),

15. 8278264 - Compositions and methods for enhancing drug delivery across and into ocular tissues (2012-10-02),

Company Overview

Kai Pharmaceuticals, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing innovative therapies for serious medical conditions. The company specializes in the research and development of novel treatments, particularly in the areas of pain management and other therapeutic domains. By leveraging advanced scientific insights and technologies, Kai Pharmaceuticals aims to address unmet medical needs and improve patient outcomes through its targeted therapeutic approaches.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

19 Patents

#68 in South San Francisco, CA

#4,095 in California

#17,123 in US

#32,623 in the World

South San Francisco, CA, United States of America

Kai Pharmaceuticals, Inc.

Forward Citations = 119

14 inventors:

Derek Maclean (11 out of 19 patents)

Qun Yin (8 out of 30 patents)

Felix D Karim (8 out of 11 patents)

4. Amos Baruch (6 out of 6 patents)

5. Kanad Das (6 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Kai Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/kai-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…